Camurus AB (publ)

OM:CAMX Stock Report

Market Cap: SEK 32.9b

Camurus Valuation

Is CAMX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CAMX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CAMX (SEK559.5) is trading below our estimate of fair value (SEK1918.4)

Significantly Below Fair Value: CAMX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CAMX?

Key metric: As CAMX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CAMX. This is calculated by dividing CAMX's market cap by their current earnings.
What is CAMX's PE Ratio?
PE Ratio123.6x
EarningsSEK 266.21m
Market CapSEK 32.90b

Price to Earnings Ratio vs Peers

How does CAMX's PE Ratio compare to its peers?

The above table shows the PE ratio for CAMX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average83.8x
SECARE Swedencare
121.4x61.4%SEK 7.5b
BIOT Biotage
47x19.5%SEK 12.1b
ALIF B AddLife
137.4x52.0%SEK 16.1b
SOBI Swedish Orphan Biovitrum
29.4x20.2%SEK 103.4b
CAMX Camurus
123.6x80.2%SEK 32.9b

Price-To-Earnings vs Peers: CAMX is expensive based on its Price-To-Earnings Ratio (123.6x) compared to the peer average (83.8x).

Price to Earnings Ratio vs Industry

How does CAMX's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
CAMX 123.6xIndustry Avg. 20.1xNo. of Companies12PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CAMX is expensive based on its Price-To-Earnings Ratio (123.6x) compared to the European Pharmaceuticals industry average (20.1x).

Price to Earnings Ratio vs Fair Ratio

What is CAMX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CAMX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio123.6x
Fair PE Ratio128.5x

Price-To-Earnings vs Fair Ratio: CAMX is good value based on its Price-To-Earnings Ratio (123.6x) compared to the estimated Fair Price-To-Earnings Ratio (128.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CAMX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 559.50
SEK 745.00
+33.2%
2.8%SEK 768.00SEK 710.00n/a6
Nov ’25SEK 600.00
SEK 753.33
+25.6%
1.7%SEK 773.00SEK 730.00n/a6
Oct ’25SEK 646.50
SEK 742.67
+14.9%
2.8%SEK 770.00SEK 710.00n/a6
Sep ’25SEK 714.50
SEK 742.67
+3.9%
2.8%SEK 770.00SEK 710.00n/a6
Aug ’25SEK 681.00
SEK 742.67
+9.1%
2.8%SEK 770.00SEK 710.00n/a6
Jul ’25SEK 594.00
SEK 621.50
+4.6%
9.4%SEK 690.00SEK 500.00n/a6
Jun ’25SEK 581.00
SEK 612.33
+5.4%
12.7%SEK 690.00SEK 445.00n/a6
May ’25SEK 498.20
SEK 577.17
+15.9%
14.4%SEK 690.00SEK 445.00n/a6
Apr ’25SEK 507.50
SEK 577.17
+13.7%
14.4%SEK 690.00SEK 445.00n/a6
Mar ’25SEK 468.80
SEK 573.00
+22.2%
15.7%SEK 690.00SEK 420.00n/a6
Feb ’25SEK 523.50
SEK 549.83
+5.0%
20.8%SEK 690.00SEK 420.00n/a6
Jan ’25SEK 538.00
SEK 508.00
-5.6%
19.8%SEK 650.00SEK 420.00n/a6
Dec ’24SEK 472.60
SEK 471.33
-0.3%
17.3%SEK 650.00SEK 420.00n/a6
Nov ’24SEK 339.00
SEK 351.33
+3.6%
6.7%SEK 380.00SEK 320.00SEK 600.006
Oct ’24SEK 310.80
SEK 320.50
+3.1%
17.4%SEK 380.00SEK 205.00SEK 646.506
Sep ’24SEK 299.40
SEK 320.50
+7.0%
17.4%SEK 380.00SEK 205.00SEK 714.506
Aug ’24SEK 294.00
SEK 320.50
+9.0%
17.4%SEK 380.00SEK 205.00SEK 681.006
Jul ’24SEK 278.60
SEK 298.17
+7.0%
14.4%SEK 332.00SEK 205.00SEK 594.006
Jun ’24SEK 277.80
SEK 298.17
+7.3%
14.4%SEK 332.00SEK 205.00SEK 581.006
May ’24SEK 233.20
SEK 284.67
+22.1%
14.1%SEK 320.00SEK 205.00SEK 498.206
Apr ’24SEK 219.40
SEK 284.67
+29.7%
14.1%SEK 320.00SEK 205.00SEK 507.506
Mar ’24SEK 228.00
SEK 284.67
+24.9%
14.1%SEK 320.00SEK 205.00SEK 468.806
Feb ’24SEK 249.40
SEK 310.00
+24.3%
5.5%SEK 330.00SEK 280.00SEK 523.505
Jan ’24SEK 252.60
SEK 305.00
+20.7%
5.1%SEK 320.00SEK 280.00SEK 538.004
Dec ’23SEK 263.40
SEK 305.00
+15.8%
5.1%SEK 320.00SEK 280.00SEK 472.604
Nov ’23SEK 252.40
SEK 283.00
+12.1%
6.6%SEK 310.00SEK 262.00SEK 339.004

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

AstraZeneca

UK£162.7b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,454.00

7D

4.0%

1Y

10.9%

Corline Biomedical

SEK 137.5m

Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.

CLBIO

SEK 6.40

7D

-2.4%

1Y

-46.7%

Devyser Diagnostics

SEK 2.2b

Develops, manufactures, and sells diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia.

DVYSR

SEK 136.00

7D

3.0%

1Y

88.9%